08:00 , Dec 8, 2011 |  BC Innovations  |  Cover Story

Big MAC attack in osteoarthritis

An international research team has shown that inhibiting the complement system slows disease progression in mice with osteoarthritis, thus pointing to complement inhibitors as potential disease modifiers. 1 Although the findings offer companies developing inhibitors...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Clinical News

Begedina regulatory update

The COMP issued a positive opinion to grant Orphan Drug designation for Adienne's Begedina to treat graft-versus-host disease (GvHD). Begedina is a murine antibody against the CD26 antigen of hematopoietic progenitor cells. COMP is part...
07:00 , Mar 29, 2010 |  BC Week In Review  |  Clinical News

Tepadina thiotepa regulatory update

The European Medicines Agency (EMA) approved an MAA from Adienne for Tepadina thiotepa as a conditioning treatment prior to autologous or allogeneic hematopoietic progenitor cell transplantation. The alkylating agent has Orphan status for the indication...
08:00 , Jan 4, 2010 |  BC Week In Review  |  Clinical News

Tepadina thiotepa regulatory update

EMEA's CHMP issued a positive opinion on an MAA from Adienne for Tepadina thiotepa as a conditioning treatment prior to autologous or allogeneic hematopoietic progenitor cell transplantation in adult and pediatric patients. The product has...
08:00 , Nov 24, 2008 |  BC Week In Review  |  Clinical News

Recombinant human minibody against complement component C5 fused with RGD-motif regulatory update

EMEA's Committee for Orphan Medical Products (COMP) issued a positive opinion to grant Orphan Drug designation for Adienne's recombinant human minibody against complement component C5 fused with RGD-motif to prevent ischemia/reperfusion injury associated with solid...
07:00 , Jul 21, 2008 |  BC Week In Review  |  Clinical News

Mubodina regulatory update

EMEA's Committee for Orphan Medical Products (COMP) issued a positive opinion to grant Orphan Drug designation for Adienne's Mubodina to treat atypical hemolytic uremic syndrome (aHUS). The recombinant human minibody C5 complement component is in...